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Abstract
PARP inhibitors can induce synthetic lethality in tumors characterized by homologous recombination deﬁciency (HRD),
which can be detected by evaluating genome-wide loss of heterozygosity (LOH). Multiple myeloma (MM) is a genetically
unstable tumor and we hypothesized that HRD-related LOH (HRD-LOH) could be detected in patient samples, supporting a
potential role for PARP inhibition in MM. Using results from targeted next-generation sequencing studies (FoundationOne®
Heme), we analyzed HRD-LOH in patients at all disease stages (MGUS (n= 7), smoldering MM (SMM, n= 30), newly
diagnosed MM (NDMM, n= 71), treated MM (TRMM, n= 64), and relapsed MM (RLMM, n= 234)) using an algorithm
to identify HRD-LOH segments. We demonstrated HRD-LOH in MM samples, increasing as disease progresses. The extent
of genomic HRD-LOH correlated with high-risk disease markers. Outcome of RLMM patients, the biggest clinical group,
was analyzed and patients with HRD-LOH above the third quartile (≥5% HRD-LOH) had signiﬁcantly worse progression-
free and overall survival than those with lower levels (p< 0.001). Mutations in key homologous recombination genes
account for some, but not all, of the cases with an excess of HRD-LOH. These data support the further evaluation of PARP
inhibitors in MM patients, particularly in the relapsed setting with a high unmet need for new treatments.
Introduction
Multiple myeloma (MM) is malignancy of plasma cells that
has been extensively characterized at a molecular level over
recent years. It can be split into groups of hyperdiploid and
non-hyperdiploid cases, the latter being deﬁned by a num-
ber of recurrent chromosomal translocations. More recently
the mutational patterns underlying MM have been descri-
bed, with those affecting KRAS and NRAS being the most
common and identiﬁed in nearly 50% of all cases [1–3].
Targeting speciﬁc mutations has therapeutic potential but is
likely to be limited by the intra-clonal and spatial genetic
heterogeneity typical of MM and the ability of the tumor
cells to signal via alternate pathways [4–7]. A different
strategy is to target the common downstream consequences
of tumor acquired mutations. In this respect, one approach
would be to target homologous recombination deﬁciency
(HRD) resulting from mutation of DNA repair pathway
genes or other mechanisms. This could be achieved utilizing
a synthetic lethal approach with PARP inhibition, as has
been demonstrated in other tumor types.
Homologous recombination repair (HRR) is an important
mechanism that maintains DNA integrity especially after
double-strand DNA breaks. The biochemical mechanisms
that underlie HRR have been well described with double-
strand breaks being detected by the MRE11-RAD50-NBS1
(MRN) complex, which then binds DNA and recruits ATM
and BRCA1. BRCA2 and its partner PALB2 localize to
exposed single-stranded DNA allowing DNA polymerase to
use the homologous DNA as a template for DNA repair.
When HRR is impaired (HRD), often as a result of genetic
changes in the key players, less-precise forms of DNA
repair are used such as non-homologous end joining. This
results in the induction of point mutations or frequent
deletions and has been implicated in the progression of a
range of cancers [8, 9]. These areas of chromosomal
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deletion can be identiﬁed and quantiﬁed by determining the
extent of loss of heterozygosity (LOH) across the genome.
Acquired mutations in BRCA1and BRCA2 result in HRD
and is a key mechanism by which a number of different
cancers progress [9]. Mutations in this limited set of genes
cannot, however, fully explain the extent of clinically
relevant HRD and a range of additional mutations have
been identiﬁed at other points in the pathway as well as
epigenetic changes that may be responsible for abnormal-
ities that would not be detectable by mutation analysis
[9–11]. The extent of genome-wide LOH provides a single
global assessment of HRD irrespective of causative lesion,
and the potential for using it as a therapeutic target [12].
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Fig. 1 a Percentage of genomic HRD-LOH by disease stage. b Per-
centage of genomic HRD-LOH by UAMS molecular subgroup. The
raw data points and the median and inter-quartile range for each data
set are shown. c Distribution of HRD-LOH shown as the percentage of
patients with HRD-LOH >1% at each genomic locus across the
autosomal chromosomes. For the acrocentric chromosomes, 13, 14,
15, 21, and 22, only the q arm was considered as estimates of HRD-
LOH in the p arm would be unreliable
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Identifying HRD is therapeutically relevant because
PARP inhibitors can induce synthetic lethality in tumors
with HRD and two such drugs are currently approved by the
FDA for the treatment of BRCA-mutated ovarian cancer,
rucaparib, and olaparib [13, 14], while niraparib is approved
for maintenance treatment in ovarian, fallopian tube, or
peritoneal cancer patients. PARP is required to repair
single-strand breaks by base excision repair, so when it is
inhibited these single-strand breaks lead to stalled replica-
tion forks and double-strand breaks. In cells with func-
tioning HRR, these can be repaired but in cells with HRD
they cannot, leading to a level of genomic instability that
overwhelms the cell resulting in apoptosis. A key example
of this therapeutic approach is provided by ovarian cancer
where patients in the ARIEL2 study with a BRCA mutation
or with a “BRCA-like” LOH-based signature but no BRCA
mutation had better responses and longer progression-free
survival to the PARP inhibitor rucaparib than BRCA wild-
type patients lacking this signature [12].
Large areas of chromosomal loss that have been pre-
viously identiﬁed in myeloma, e.g. del[1p], del[13q] are
well recognized and have been associated with adverse
outcomes [15, 16]. Smaller regions of loss across the gen-
ome that may be related to HRD are less well characterized.
Mutations in some DNA damage response genes have been
identiﬁed but the wider extent of the LOH phenotype is
unknown. In this study, we have characterized and quanti-
ﬁed the presence of global HRD-related LOH (HRD-LOH)
in MM patients and have used it as an indicator of HRD that
could provide a therapeutic rational for PARP inhibition in
a subgroup of cases.
Methods
We analyzed 406 myeloma cases treated at the University
of Arkansas for Medical Sciences (UAMS) at all stages of
disease: monoclonal gammopathy of undetermined sig-
niﬁcance (MGUS, n= 7), smoldering myeloma (n= 30),
newly diagnosed myeloma (n= 71), treated myeloma (n=
64), and relapsed myeloma (RLMM, n= 234). CD138-
positive plasma cells were selected from patient samples
and DNA extracted. DNA underwent targeted next-
generation sequencing (FoundationOne® Heme) inter-
rogating 405 cancer-related genes and 3543 single-
nucleotide polymorphisms (SNPs) across the genome as
previously described [17, 18]. Targeted sequencing was
performed as part of patient disease work-up and review of
the data was approved by the UAMS institutional review
board.
To identify genomic LOH, an algorithm was developed
to quantify the percentage of the genome interrogated with
LOH. Brieﬂy, minor-allele frequencies of SNPs and the
copy-number proﬁle of the 22 autosomal chromosomes
were used to identify LOH. We excluded from this per-
centage events that are unlikely to be caused by HRD
mechanisms but are common in myeloma, such as whole-
chromosome or chromosome-arm loss. The percentage of
genomic HRD-LOH for each sample was calculated as the
Fig. 2 a Event-free survival by genomic HRD-LOH. Kaplan–Meier
plots demonstrating the probability of survival for those patients with
genomic HRD-LOH <5% (n= 150, median 0.512 years) vs. ≥5%
(n= 65, median 0.197 years). Hazard ratio 1.79 (1.3, 2.5); p=
0.00065. b Overall survival by genomic HRD-LOH. Kaplan–Meier
plots demonstrating the probability of survival for those patients with
genomic HRD-LOH <5% (n= 150, median 1.266 years) vs. ≥5%
(n= 65, median 0.939 years). Hazard ratio 2.18 (1.5, 3.2); p= 8.23e−05
Table 1 Multivariate Cox regression analysis of event-free and overall
survival
Event-free survival Wald interaction
p value
p value of HRD-LOH
contribution
HRD-LOH*PR <0.0001 0.01
HRD-
LOH*GEP70
<0.0001 0.08
HRD-LOH*PI <0.0001 0.02
Overall survival Wald interaction
p value
p value of HRD-LOH
contribution
HRD-LOH*PR <0.0001 0.002
HRD-
LOH*GEP70
<0.0001 0.39
HRD-LOH*PI <0.0001 0.04
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sum of the lengths of the HRD-LOH segments divided by
the length of the interrogated genome. An in-depth
description of the algorithm can be found in Swisher
et al. [12], supplemental information.
Percentage HRD-LOH was examined by the presence or
absence of a deleterious mutation in 1 of 23 homologous
recombination related genes that had been interrogated by
NGS: ATM, ATR, ATRX, BARD1, BAP1, BLM, BRCA1,
BRCA2, BRIP1, CDK12, CHEK1, CHEK2, FANCA,
FANCC, FANCD2, FANCE, FANCF, FANCG, FANCL,
MRE11A, PALB2, RAD50, RAD51. Matched gene expres-
sion proﬁling (GEP) was performed using Affymetrix U133
Plus 2.0 Arrays and GEP70-deﬁned risk status, proliferation
index (PI), and molecular subgroups were calculated, as
previously described [19, 20].
Results
The median level of genomic HRD-LOH was 2.8% across
all samples with a subset of 25% of patients having levels of
>5% and around 4% of patients having high levels at
>10%. There was no difference in HRD-LOH between
genders. The level of HRD-LOH increased signiﬁcantly
with increasing disease stage from a median of 0.3% in
MGUS to 3.1% in RLMM, (analysis of variance; F= 4.7, p
= 0.0011), Fig. 1a, suggesting that HRD-LOH may be
acquired throughout disease evolution as a result of the
acquisition of additional genetic events.
To examine the association of molecular subgroup with
the extent of HRD-LOH, we determined the distribution of
HRD-LOH across the UAMS molecular subgroups [20].
We found that HRD-LOH was highest in the proliferation
(PR), MAF (MF), and MMSET/FGFR3 (MS) subgroups,
Fig. 1b. It is notable that higher levels of HRD-LOH were
seen in these subgroups associated with an increased inci-
dence of high-risk disease. Consistent with this observation,
the extent of HRD-LOH correlated signiﬁcantly with
GEP70-deﬁned risk status [21], (R= 0.42, p= 7× 10−15).
There was also a signiﬁcant correlation with the gene
expression deﬁned proliferation index (PI) [22], another
marker of high-risk disease (R= 0.39, p= 2× 10−12).
HRD-LOH was distributed as shown in Fig. 1c. The pattern
of distribution was not dominated by speciﬁc loci with high
rates of HRD-LOH, which was spread throughout the
genome.
We went on to examine the association of HRD-LOH
with PFS and OS in the largest group of patients, those with
RLMM. We found that patients with levels of HRD-LOH in
the top quartile for the whole population (≥5%) had a sig-
niﬁcantly shorter event-free survival (EFS) than those with
lower levels. Patients with HRD-LOH <5% (n= 150), had
a median EFS of 0.51 years, while those with HRD-LOH
≥5% (n= 65) had a median EFS of 0.20 years (HR 1.79, p
= 6.5× 10−4). This signal was stable across cutoff values
from 1 to 9% with the optimal cut point deﬁned as 5%,
Fig. 2a. A similar pattern was seen for overall survival (OS).
Patients with HRD-LOH <5% (n= 150), had a median OS
of 1.3 years, while those with HRD-LOH ≥5% (n= 65 had
a median OS of 0.94 years (HR 2.18, p= 8.2× 10−5)).
There was again a signiﬁcant difference seen at all cutoff
values 1–9% and an optimal cutoff of 5%, Fig. 2b. In a
multivariate Cox regression analysis, we ﬁnd that HRD-
LOH as a biomarker of poor prognosis overlaps in large
parts with other prognostic factors, such as the PR sub-
group, GEP70, and PI. In particular, GEP70 captures the
patient population with poor outcome better than a combi-
nation of HRD-LOH and GEP70, as indicated by a non-
signiﬁcant p value for HRD-LOH in the multivariate model
for both OS and EFS. In combination with PR and PI, LOH
Fig. 3 a Genomic HRD-LOH across all myeloma samples with those
carrying a mutation in a gene associated with homologous recombi-
nation indicated in black (HRmut). b Genomic HRD-LOH by presence
of HRmut or wild type (HRwt). Wilcoxon test for difference between
groups, p= 0.056. c Genomic HRD-LOH by presence of a BRCA1/2
mutation. Wilcoxon test for difference between groups, p= 0.383. The
raw data points and the median and inter-quartile range for each data
set are shown. The number and percentage of patients with a mutation
identiﬁed in each of the genes indicated is shown in the table below the
ﬁgure
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makes a small but signiﬁcant contribution to enhancing the
biomarkers of poor prognosis PR and PI on their own
(Table 1).
We next analyzed paired mutation data, which was
available for 311/406 cases. Deleterious mutations in any of
the 23 genes sequenced that have been associated with
homologous recombination (ATM, ATR, ATRX, BARD1,
BAP1, BLM, BRCA1, BRCA2, BRIP1, CDK12, CHEK1,
CHEK2, FANCA, FANCC, FANCD2, FANCE, FANCF,
FANCG, FANCL, MRE11A, PALB2, RAD50, and RAD51)
were identiﬁed in 5.1% (16/311) of patients, Fig. 3a. ATM
(4/311, 1.3%) and BRCA2 (5/311, 1.6%) were the most
frequently mutated genes. The sample with the second
highest HRD-LOH of 14.2% had a deleterious ATM
mutation. Samples with deleterious mutations in any
homologous recombination gene had a higher median
genomic HRD-LOH than those without (4.66 vs. 2.85%, p
= 0.056), Fig. 3b. This comparison met statistical sig-
niﬁcance when limited to mutations found in genes most
highly associated with homologous recombination (ATM,
BARD1, BRCA1, BRCA2, BRIP1, CDK12, CHEK2,
FANCA, PALB2, RAD51, p= 0.049). The difference was
also apparent when BRCA1/2 deleterious mutations were
examined alone Fig. 3c. As can be seen in Fig. 3a mutations
in HR genes could account for some, but not all, of the top
quartile of HRD-LOH cases suggesting there are other
mechanisms mediating this phenotype.
Conclusions
We show, for the ﬁrst time in myeloma, that it is possible to
quantitate the extent of genome-wide HRD-LOH and that
there is a group of patients with an excess of such change
that is associated with impaired outcomes. Genome-wide
HRD-LOH increases as the disease progresses and also
within higher risk groups. The median level of HRD-LOH
across the population as a whole is relatively low at 2.8%
compared to ovarian cancer (~16%), but is still a signiﬁcant
pathologic mechanism in the cases with high levels and
poor outcomes.
We show that mutations in key homologous recombi-
nation genes account for some but not all of the cases with
an excess of HRD-LOH suggesting there are other
mechanisms that are also responsible for the phenotype.
These may include epigenetic phenomena such as homo-
logous recombination gene silencing by DNA methylation
as seen in breast and ovarian cancer [23], but these
mechanisms were not analyzed in this study.
The group of patients identiﬁed with an excess of HRD-
LOH may have associated features of 'BRCAness' and so
may be amenable to PARP inhibition. The concept of
BRCAness has been developed in ovarian cancer where
cases share features with those with mutational inactivation
of BRCA genes, such as sensitivity to platinum-based
therapies and PARP inhibitors. In ovarian cancer, the
optimal cutpoint for percentage of genome-wide HRD-LOH
that predicted response to PARP inhibitor therapy was
ascertained to be 14% within the ARIEL2 trial [12]. While
we have shown the distribution and extent of HRD-LOH in
myeloma, as well as the optimum cutpoint associated with
adverse outcomes, the relevant cutoff to predict response to
PARP inhibition in this disease will need to be further
explored in clinical studies.
A number of lines of pre-clinical evidence support a
clinical exploration of PARP inhibitors in myeloma. In vitro
responses in myeloma cell lines and primary patient sam-
ples have been studied using the PARP1/2 inhibitor ABT-
888. Despite demonstration of induction of DNA damage,
the use of ABT-888 as a single agent was not effective, but
it is unknown whether these cells had either mutations in
DNA repair genes or had an excess of HRD-LOH [24, 25].
Sensitivity to PARP inhibition was induced, either by
chemically inhibiting the DNA damage response pathway
[25] or by inducing increased BRCAness with the protea-
some inhibitor bortezomib [24]. In both studies, this syn-
thetic lethal effect was associated with a downregulation of
HRR genes. Identifying patients with inherent BRCAness
who may be more likely to respond to single agent PARP
inhibition may prove fruitful. In addition, expanding such
studies to utilize combinations with both cisplatin and
proteasome inhibition would be clinically very useful
because this type of genomic instability is more prevalent in
high-risk disease states where therapeutic options are
limited.
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